Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENTORA vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, binding to and activating opioid receptors in the brain and spinal cord, leading to analgesia and sedation.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain
Mild to moderate pain,Fever
For opioid-tolerant adults: 100 mcg (one tablet) placed in buccal cavity; titrate upward in increments of 100 mcg per breakthrough pain episode, with minimum 2-hour interval between doses; maximum 4 doses per day.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life is approximately 2–4 hours in adults, but can range from 2 to 6 hours depending on hepatic clearance. In elderly or hepatically impaired patients, half-life may be prolonged. The rapid initial decline is due to redistribution, and the terminal phase reflects slow elimination from deep compartments.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
FENTORA is primarily metabolized by CYP3A4 to norfentanyl and other metabolites.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily renal: Approximately 75% of the dose is excreted in urine as metabolites (mostly norfentanyl, despropionylfentanyl, and hydroxyfentanyl), with less than 7% as unchanged fentanyl. Fecal elimination accounts for about 9%.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Approximately 80–85% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein (AAG). Binding is concentration-dependent and may decrease in conditions with low albumin or elevated AAG.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Volume of distribution (Vd) is 3–6 L/kg, indicating extensive tissue distribution. Large Vd reflects high lipophilicity and rapid uptake into tissues such as fat and muscle, contributing to redistribution and prolonged effects with repeated doses.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Buccal administration: Absolute bioavailability is approximately 65–70% due to first-pass metabolism and some swallowed drug. Sublingual delivery is similar, but variability is high. Compared to IV, buccal bioavailability is consistent at ~65%.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
For GFR <30 m L/min: initiate at 50 mcg (half a 100 mcg tablet) and titrate cautiously; no specific adjustment for GFR 30-89 m L/min.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class A or B: initiate at 50 mcg and titrate cautiously; Child-Pugh Class C: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not approved for use in pediatric patients (safety and efficacy not established).
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Initiate at 50 mcg in patients aged ≥65 years and titrate cautiously; monitor for respiratory depression and cognitive impairment.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
WARNING: RISK OF MEDICATION ERRORS; ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; RISK OF SEROTONIN SYNDROME; RISK OF ADRENAL INSUFFICIENCY; SEVERE HYPOTENSION; GASTROINTESTINAL ADVERSE REACTIONS; SEIZURES; AND INCREASED INTRACRANIAL PRESSURE, HEAD INJURY, OR IMPAIRED CONSCIOUSNESS.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Life-threatening respiratory depression,Addiction, abuse, and misuse,Risk of medication errors (dosing and product confusion),Accidental exposure (especially in children),Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Interaction with alcohol,Risk of serotonin syndrome,Risk of adrenal insufficiency,Severe hypotension,Gastrointestinal adverse reactions (e.g., constipation),Seizures,Increased intracranial pressure,Use in patients with head injury or impaired consciousness
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Opioid non-tolerant patients,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Known hypersensitivity to fentanyl or any components of FENTORA
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid grapefruit juice and grapefruit products as they inhibit CYP3A4 and can increase fentanyl levels, raising risk of respiratory depression and QT prolongation. Do not consume alcohol; additive CNS depression may occur. No other known significant food interactions; however, avoid high-fat meals immediately before or after administration as they may alter absorption.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Insufficient human data; animal studies show increased skeletal anomalies and reduced fetal weight at high doses. Fentanyl is not a major teratogen but chronic use may cause neonatal opioid withdrawal syndrome (NOWS) in third trimester. Avoid in pregnancy unless benefits outweigh risks.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Fentanyl is excreted in breast milk; M/P ratio not established but assumed similar to parenteral fentanyl (M/P ~0.5-1). Effect on infant minimal with single use, but chronic use may lead to opioid exposure. Use caution and monitor infant for sedation and respiratory depression.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No specific dose adjustments for fentanyl in pregnancy; pharmacokinetic changes may require higher doses due to increased clearance and volume of distribution. Use lowest effective dose and titrate to effect.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
FENTORA (fentanyl buccal tablet) is an immediate-release opioid indicated only for breakthrough pain in opioid-tolerant cancer patients. Do not use in opioid-naive patients due to risk of fatal respiratory depression. The tablet must not be split, crushed, or chewed; place in buccal cavity. Onset of analgesia occurs within 15 minutes. Due to QT prolongation risk, avoid use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) and in patients with electrolyte abnormalities. Follow single-tablet administration and wait at least 2 hours before treating another episode. Tear the blister pack before placing; do not store opened blister.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Use only for breakthrough pain if you are already taking around-the-clock opioid medication and are tolerant to it.,Do not use this medicine if you have not taken opioids before; it can cause life-threatening breathing problems.,Place the entire tablet in your cheek pouch above a back molar; do not crush, chew, or swallow it.,Allow tablet to dissolve completely; do not eat or drink until it has fully dissolved (about 14–25 minutes).,If you get more than one breakthrough pain episode per day, contact your doctor; do not increase the dose on your own.,Store in original sealed blister pack; keep out of reach of children and dispose of unused tablets properly.,Avoid alcohol and grapefruit juice while using this medicine.,Do not drive or operate machinery until you know how this medicine affects you.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENTORA vs ACEPHEN, answered by our medical review team.
FENTORA is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, binding to and activating opioid receptors in the brain and spinal cord, leading to analgesia and sedation.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENTORA and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENTORA is: For opioid-tolerant adults: 100 mcg (one tablet) placed in buccal cavity; titrate upward in increments of 100 mcg per breakthrough pain episode, with minimum 2-hour interval between doses; maximum 4 doses per day.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FENTORA and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FENTORA is classified as Category C. Insufficient human data; animal studies show increased skeletal anomalies and reduced fetal weight at high doses. Fentanyl is not a major teratogen but chronic use may cause neonat. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.